CompletedPhase 2/3

18F-Fluorocholine for the Detection of Parathyroid Adenomas

United States98 participantsStarted 2016-09-21

Plain-language summary

The investigators are studying the ability of F18 labeled fluorocholine PET to localize parathyroid adenomas in patients with hyperparathyroidism prior to surgery.

Who can participate

Age range13 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Biochemically proven hyperparathyroidism and an indication for surgery * Age \>= 13 years old * Karnofsky performance status of \> 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent). * Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: * Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the PET scanner due to BMI. * Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.). * Inability to complete the needed investigational due to other reasons (severe claustrophobia, radiation phobia, etc.). * Pregnancy.

What they're measuring

Proportion of True Positives for the Overall Detection of the Abnormal Parathyroid Adenoma

Timeframe: Up to 1 year

Proportion of True Positives for the Detection of the Abnormal Parathyroid Adenoma Using Sestamibi Imaging

Timeframe: Up to 1 year

Trial details

NCT IDNCT03764007

SponsorThomas Hope

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-05-31

Results submitted2021-08-25

View on ClinicalTrials.gov More Hyperparathyroidism, Primary trials